Clinical Trials Logo

Aggression clinical trials

View clinical trials related to Aggression.

Filter by:

NCT ID: NCT01547052 Completed - Clinical trials for Childhood Aggression

Adapting Dialectical Behavior Therapy for Children in Residential Care

DBT-C
Start date: April 2011
Phase: N/A
Study type: Interventional

I: Conduct Pilot Randomized Clinical Trial of Dialectical Behavior Therapy for children (DBT-C) in residential as compared with Treatment-As-Usual (TAU) (60 children in DBT-C and 60 children in the comparison condition). II: Finalize therapist training manuals and educational materials to guide selection, training, and supervision of treatment providers.

NCT ID: NCT01538641 Completed - Clinical trials for Relapsing Aggressive Non-Hodgkin's Lymphoma

Phase II Evaluation of Gemcitabine- Rituximab-Oxaliplatin Combination (GROC) in Relapsed Aggressive Lymphomas

Start date: October 2003
Phase: Phase 2
Study type: Interventional

Study Proposal: Other drugs where synergy with Gemcitabine has been observed are Cisplatinum, Taxol, Taxotere, Etoposide and alkylating agents. However in view of Oxaliplatin's superior activity as a single agent against lymphoma, the combination of Gemcitabine with Oxaliplatin is more attractive and should be explored in this group of disorders. Based on these data and considering the advantage of its favorable toxicity profile, we propose a phase II study in patients with either refractory or relapsing aggressive non-Hodgkin's lymphomas including peripheral T-cell lymphomas which are known to have a poor outcome when compared with equivalent aggressive B-cell lymphomas.

NCT ID: NCT01527045 Completed - Clinical trials for Chronic Lymphocytic Leukemia

Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies

Start date: September 25, 2012
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well donor atorvastatin treatment works in preventing severe graft-versus-host disease (GVHD) after nonmyeloablative peripheral blood stem cell (PBSC) transplant in patients with hematological malignancies. Giving low doses of chemotherapy, such as fludarabine phosphate, before a donor PBSC transplantation slows the growth of cancer cells and may also prevent the patient's immune system from rejecting the donor's stem cells. The donated stem cells may replace the patient's immune cells and help destroy any remaining cancer cells (graft-versus-tumor effect). Sometimes the transplanted cells from a donor can also cause an immune response against the body's normal cells (GVHD). Giving atorvastatin to the donor before transplant may prevent severe GVHD.

NCT ID: NCT01519193 Completed - Clinical trials for Post-Traumatic Stress Disorder

Treatment of Aggressive Behavior and Post-Traumatic Stress Disorder

Start date: January 2011
Phase: Phase 2
Study type: Interventional

Street children and children of vulnerable families in conflict or former conflict regions are often exposed to multiple traumatic events and situations in which they are forced to engage in violent behavior. The Narrative Exposure Therapy for violent offenders (NETvo) aims to reduce both PTSD symptoms and aggressive behavior. It helps the children to anchor fearful experiences and positive emotions linked to violent behaviour in the past. Additionally, visions for the future are developed in order to foster successful reintegration into society.

NCT ID: NCT01510808 Recruiting - Clinical trials for Aggressive Periodontitis

The Affect of Orthodontic Treatment on the Periodontal Status of Patients With Aggressive Periodontitis

Start date: January 2012
Phase: N/A
Study type: Observational

Orthodontic Treatment will affect the periodontal status of periodontally treated Aggressive Periodontitis patients.

NCT ID: NCT01483521 Completed - Aggression Clinical Trials

Infant Psychiatry Home Visitation Program

Start date: April 2009
Phase: N/A
Study type: Interventional

This is a proposed home visitation program for families of children with externalizing behaviors who are on the wait list for psychiatric assessment at BC Children's hospital. The aim of this program is to implement and evaluate a home visitation strategy in order to support those waiting up to four months to consult a psychiatrist.

NCT ID: NCT01478542 Completed - Clinical trials for CD20+ Aggressive B-Cell Lymphoma

OPTIMAL>60 / DR. CHOP, Improvement of Therapy of Elderly Patients With CD20+ DLBCL Using Rituximab Optimized and Liposomal Vincristine

OPTIMAL>60
Start date: November 2011
Phase: Phase 3
Study type: Interventional

The purpose of this study is to improve the outcome of elderly patients with CD20-Aggressive B-Cell Lymphoma and to reduce the toxicity of standard used Immuno-Chemotherapy by using an optimised schedule of the monoclonal antibody Rituximab, substituting conventional by Liposomal Vincristine and by a PET-guided reduction of therapy in Combination with Vitamin D Substitution.

NCT ID: NCT01464216 Active, not recruiting - Prostatic Neoplasms Clinical Trials

MRI for Assessment of Hypoxia-Induced Prostate Cancer Aggressiveness

FuncProst
Start date: October 2011
Phase:
Study type: Observational

The purpose of the study is to combine and correlate data from morphological and functional MRI, molecular signatures of tumor hypoxia, the presence of micrometastases and tumor hypoxia with the goal being predicting of prostate cancer aggressiveness.

NCT ID: NCT01459835 Completed - Aggression Clinical Trials

Media Impact on Preschool Behavior

Start date: June 2010
Phase: N/A
Study type: Interventional

This study tests the hypothesis that modifying the media diet of preschool children so that they watch more prosocial programming and less violent programming will result in decreased aggression and increased prosocial behavior.

NCT ID: NCT01416064 Completed - Clinical trials for Impulsive Aggression Comorbid With ADHD in Children

Open-Label, Extension Study to 810P202

Start date: September 2011
Phase: Phase 2
Study type: Interventional

Open-label, extension study for subjects that completed 810P202 to examine long term safety and tolerability of repeated dosing of SPN-810M as an adjunctive therapy in children with Impulsive Aggression Comorbid with Attention-Deficit/Hyperactivity Disorder (ADHD).